Assembly Biosciences, Inc. ASMB
Assembly Biosciences, Inc. (Nasdaq: ASMB) is an infectious disease drug developer. Its lead program, ABI-6250, is in Phase 1 for chronic hepatitis delta virus (HDV) infection; planned PBC/PSC. Its next catalyst on record is ABI-6250: initiate Phase 2 study in HDV (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ABI-6250 — initiate Phase 2 study in HDV (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ABI-6250 | chronic HDV | small molecule | Phase 1 |
| ABI-4334 | chronic HBV (capsid assembly modulator) | small molecule | Phase 1 |
| ABI-6250 | PBC / PSC (cholestatic liver disease) | small molecule | Pre-clinical |
| ABI-7272 | transplant-associated herpesviruses | small molecule | Pre-clinical |
Recent results and decisions
- Dec 8, 2025positive Interim Phase 1b of weekly oral ABI-1179 in recurrent genital herpes: 98% reduction in HSV-2 shedding rate vs placebo (p<0.01) at 50 mg and 91% reduction in virologically confirmed lesion rate (p<0.01).
In the ABI-1179 study, highly potent antiviral activity was observed with a 98% reduction in HSV-2 shedding rate compared to placebo (p<0.01) over the 29-day evaluation period in the 50 mg weekly dose cohort.
Filing - Dec 8, 2025positive Interim Phase 1b of monthly oral ABI-5366: 76% reduction in HSV-2 shedding rate (p<0.01) and 88% reduction in virologically confirmed genital lesion rate (p=0.01) vs placebo.
In the ABI-5366 monthly dose cohort, potent antiviral activity was observed, with a 76% reduction in HSV-2 shedding rate compared to placebo (p<0.01) over the 29-day evaluation period.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.